Autoimmune type 1 diabetes in the era of disease‐modifying immune therapy

Michels, Aaron W., Gottlieb, Peter A., Nelson, Bryce and Dayan, Colin ORCID: https://orcid.org/0000-0002-6557-3462 2025. Autoimmune type 1 diabetes in the era of disease‐modifying immune therapy. Diabetes/Metabolism Research and Reviews 41 (7) , e70091. 10.1002/dmrr.70091 Item availability restricted.

PDF - Published Version Restricted to UNSPECIFIED Available under License Creative Commons Attribution. Download (1MB)

Abstract

Disease‐modifying therapies have been used to treat the underlying causes of autoimmune diseases for over half a century. However, until recently, type 1 diabetes (T1D), the autoimmune form of diabetes, had not entered this therapeutic landscape. The approval of teplizumab, an anti‐CD3 monoclonal antibody and the first disease‐modifying therapy for use in individuals with preclinical T1D, has caused a major shift in the way healthcare providers can treat the T1D disease course. In this review, we discuss the chronic autoimmune nature of T1D and provide an overview of disease‐modifying therapies that are under investigation to target the autoimmune mechanisms in T1D to preserve residual beta‐cell function and prevent disease progression. The considerations for implementing these therapies into clinical practice are also discussed.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Schools > Medicine
Additional Information:	License information from Publisher: LICENSE 1: URL: http://creativecommons.org/licenses/by/4.0/
Publisher:	Wiley
ISSN:	1520-7552
Date of First Compliant Deposit:	16 October 2025
Date of Acceptance:	16 September 2025
Last Modified:	16 Oct 2025 10:15
URI:	https://orca.cardiff.ac.uk/id/eprint/181708

Actions (repository staff only)

Edit Item